Replies to post #113395 on Biotech Values

[oc631]

Such a distinction is inconsequential in the overall scheme of things. In the unlikely (IMO) event that Teva gets FDA approval for Lovenox, MNTA will presumably adjust its operating costs to a level commensurate with lower revenues.

You may be overlooking the increase in legal fees as protection of MNTA's IP begins in earnest.